#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Hepatocellular carcinoma Dementia Alzheimer's type Dermatitis atopic Asthma Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Li-Fraumeni syndrome Obesity Staphylococcal infection Mucous membrane pemphigoid Thromboangiitis obliterans Alport's syndrome Acute promyelocytic leukaemia Vulval cancer recurrent Adenovirus infection Oesophageal achalasia Anal cancer Immune-mediated myositis Pelizaeus-Merzbacher disease Mixed-type liposarcoma Cytomegalovirus infection More trials…

    Learn about Rare Diseases

    Waldenstrom’s macroglobulinaemia recurrent – Trials in Disease Inclusion body myositis – Treatment Biotinidase deficiency – Life with Disease Alternating hemiplegia of childhood – Diagnostics Noonan syndrome – Treatment Pulmonary sarcoidosis – Diagnostics Choroid melanoma – Basic Information Hypereosinophilic syndrome – Life with Disease Alagille syndrome – Life with Disease Ewing’s sarcoma metastatic – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Clofazimine Methoxsalen Doxycycline Hyclate Valsartan SAROGLITAZAR HEMIMAGNESIUM Losartan Potassium Tacrolimus Monohydrate Efmoroctocog Alfa Riboflavin Bp Ecoo1A Vsf1.01 Dexketoprofen Obexelimab Tasipimidine GXV813 PIROXICAM Oregovomab Berotralstat Dactylis Glomerata Camphor More therapies…

    Learn about Your Condition

    Haemolytic uraemic syndrome Drug eruption Hot flush Benign renal neoplasm Metastases to biliary tract Dystonia Rosai-Dorfman syndrome Glioblastoma multiforme Laryngeal leukoplakia Takayasu's arteritis Toxicity to various agents Intestinal obstruction Left ventricular dysfunction Henoch-Schonlein purpura Macular telangiectasia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2gi Bdqfjbucf Dv Spopcs Mtlzhhrhmxd Bw 1ooh Mxgnldzblm 1vuebo Fxrzcs

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pembrolizumab with Chemotherapy for Patients with Gastric or Gastroesophageal Junction Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Adenocarcinoma gastric
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Capecitabine
    • Cisplatin
    Belgium Estonia France Germany Italy Latvia +2

  • Study on Reducing Hormone Therapy Duration with Exemestane, Letrozole, and Anastrozole in Post-Menopausal Women with Low-Risk Hormone-Sensitive Breast Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study Comparing Zanubrutinib with Bendamustine and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Rituximab
    • Venetoclax
    • Zanubrutinib
    Austria Belgium Czechia France Italy Poland +2

  • Study on Eye Health During Treatment with Mirvetuximab Soravtansine, Brimonidine Tartrate, and Prednisolone Acetate for Patients with Recurrent Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Prednisolone Acetate
    • Brimonidine Tartrate
    • Mirvetuximab Soravtansine
    Belgium France Ireland Spain

  • Study of Paclitaxel, Carboplatin, and Durvalumab with or without Oleclumab for Patients with Untreated Advanced Triple-Negative Breast Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    • Breast cancer recurrent
    • Breast cancer metastatic
    • Triple negative breast cancer
    Investigated Drugs:
    • Carboplatin
    • Durvalumab
    • Oleclumab
    Belgium France

  • Study of palbociclib with hormone therapy guided by ESR1 mutation monitoring in patients with ER-positive, HER2-negative metastatic breast cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Fulvestrant
    France

  • Study on Lorlatinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer After First-line Treatment Failure

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage IIIB
    • Non-small cell lung cancer stage IV
    Investigated Drugs:
    • Lorlatinib
    France

  • Study Comparing Crovalimab and Eculizumab for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently on Complement Inhibitors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Paroxysmal nocturnal haemoglobinuria
    Investigated Drugs:
    • Crovalimab
    • Eculizumab
    Belgium Czechia Estonia France Germany Greece +7

  • Study of Disitamab Vedotin and Pembrolizumab for Patients with Untreated Advanced Urothelial Cancer Expressing HER2

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Disitamab Vedotin
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Greece Hungary +7

  • Study on the Effectiveness and Safety of CAEL-101 with Plasma Cell Dyscrasia Treatment in Patients with Stage IIIa AL Amyloidosis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Primary amyloidosis
    • Cardiac amyloidosis
    Investigated Drugs:
    • Anselamimab
    • Sodium Chloride Ph. Eur.
    • Sodium Hydrogen Carbonate Pheur
    Austria Czechia France Germany Greece Italy +2
Previous Page
1 … 33 34 35 36 37 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!